Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bevacizumab Biosimilar (Rotterdam Biologics), bevacizumab biosimilar(Rotterdam Biologics B.V), 贝伐珠单抗生物类似药(Rotterdam Biologics) + [1] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Wet age-related macular degeneration | NDA/BLA | European Union | 16 Dec 2021 |






